{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:26:12Z","timestamp":1767961572984,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.vaccine.2009.05.045","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T11:50:00Z","timestamp":1244634600000},"page":"4537-4542","source":"Crossref","is-referenced-by-count":13,"title":["Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines"],"prefix":"10.1016","volume":"27","author":[{"given":"P.M.","family":"Parreiras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Sirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Arciniega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2009.05.045_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1469-0691.2002.00500.x","article-title":"Anthrax in Europe: its epidemiology, clinical characteristics, and role in bioterrorism","volume":"8","author":"Schmid","year":"2002","journal-title":"Clin Microbiol Infect"},{"issue":"RR15","key":"10.1016\/j.vaccine.2009.05.045_bib2","first-page":"1","article-title":"Use of anthrax vaccine in the United States","volume":"49","author":"Advisory Committee on Immunization Practices","year":"2000","journal-title":"MMWR"},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.045_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3201\/eid0905.020477","article-title":"Endemic, notifiable bioterrorism-related diseases, United States, 1992\u20131999","volume":"9","author":"Chang","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.045_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.278.5.418","article-title":"Iraq's biological weapons. The past as future?","volume":"278","author":"Zilinskas","year":"1997","journal-title":"JAMA"},{"issue":"41","key":"10.1016\/j.vaccine.2009.05.045_bib5","first-page":"893","article-title":"Recognition of illness associated with the intentional release of a biologic agent","volume":"50","author":"CDC","year":"2001","journal-title":"MMWR"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.045_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.287.7.898","article-title":"Bioterrorism preparedness and response: clinicians and public health agencies as essential partners","volume":"287","author":"Gerberding","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.045_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/153871303769201842","article-title":"Biodefense R & D: anticipating future threats, establishing a strategic environment","volume":"1","author":"Smith","year":"2003","journal-title":"Biosecur Bioterror"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2009.05.045_bib8","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0264-410X(03)00109-9","article-title":"Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants","volume":"21","author":"Jendrek","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.05.045_bib9","unstructured":"21. CFR Part 620.20-24, Food and Drug Administration, HHS. Code of Federal Regulations. Subpart C\u2014Anthrax vaccine adsorbed, April 1, 1992; pp. s71\u201372."},{"key":"10.1016\/j.vaccine.2009.05.045_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/JB.85.1.230-236.1963","article-title":"Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man","volume":"85","author":"Puziss","year":"1963","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.045_bib11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect Immun"},{"issue":"22","key":"10.1016\/j.vaccine.2009.05.045_bib12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.045_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pds.712","article-title":"Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"11","author":"Sever","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.045_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/IAI.60.2.662-668.1992","article-title":"Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants","volume":"60","author":"Ivins","year":"1992","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.045_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biologicals.2004.03.002","article-title":"Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice","volume":"32","author":"Pombo","year":"2004","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.045_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"issue":"16","key":"10.1016\/j.vaccine.2009.05.045_bib17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2004.10.014","article-title":"Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants","volume":"23","author":"Berthold","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.045_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-1759(95)00067-K","article-title":"Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model","volume":"183","author":"Reizenstein","year":"1995","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.045_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","article-title":"Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill","volume":"119","author":"Hansen","year":"1989","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2009.05.045_bib20","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/JCM.32.10.2441-2447.1994","article-title":"Determination of parallelism and nonparallelism in bioassay dilution curves","volume":"32","author":"Plikaytis","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.045_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1191\/096228099673819272","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2009.05.045_bib22","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","article-title":"Development of an in vitro-based potency assay for anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.05.045_bib23","unstructured":"US Code of Federal Regulations, Title 21, Part 601, Subpart H. April 1, 2008."},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.045_bib24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Participating laboratories. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.045_bib25","first-page":"73","article-title":"Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccines\u2014part 2","author":"Wisnes","year":"2006","journal-title":"Pharmeuropa Bio"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.045_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/clinchem\/25.3.432","article-title":"Incorrect least-squares regression coefficients in method-comparison analysis","volume":"25","author":"Cornbleet","year":"1979","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.045_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lin","year":"1989","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.045_bib28","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1086\/423937","article-title":"Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax","volume":"190","author":"Quinn","year":"2004","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.045_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CDLI.12.6.713-721.2005","article-title":"Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis","volume":"12","author":"Pittman","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"33\u201334","key":"10.1016\/j.vaccine.2009.05.045_bib30","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.045_bib31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax\u00ae anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.045_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/CVI.00015-08","article-title":"Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background","volume":"15","author":"Abboud","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2009.05.045_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2307\/2987937","article-title":"Measurement in medicine: the analysis of method comparison studies","volume":"32","author":"Altman","year":"1983","journal-title":"Statistician"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:02:13Z","timestamp":1589893333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":33,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0264410X09006707"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}